As of 2024-07-27, the EV/EBITDA ratio of Ultragenyx Pharmaceutical Inc (RARE) is -6.60. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RARE's latest enterprise value is 4,083.95 mil USD. RARE's TTM EBITDA according to its financial statements is -619.22 mil USD. Dividing these 2 quantities gives us the above RARE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.4x - 17.5x | 13.7x |
| Forward P/E multiples | 20.9x - 24.8x | 23.7x |
| Fair Price | (137.02) - (114.91) | (122.59) |
| Upside | -405.4% - -356.2% | -373.3% |
| Date | EV/EBITDA |
| 2024-07-26 | -6.60 |
| 2024-07-25 | -6.63 |
| 2024-07-24 | -6.63 |
| 2024-07-23 | -6.64 |
| 2024-07-22 | -6.53 |
| 2024-07-19 | -6.25 |
| 2024-07-18 | -6.28 |
| 2024-07-17 | -6.45 |
| 2024-07-16 | -6.66 |
| 2024-07-15 | -6.53 |
| 2024-07-12 | -6.64 |
| 2024-07-11 | -6.45 |
| 2024-07-10 | -6.23 |
| 2024-07-09 | -6.20 |
| 2024-07-08 | -6.09 |
| 2024-07-05 | -5.99 |
| 2024-07-03 | -5.89 |
| 2024-07-02 | -6.01 |
| 2024-07-01 | -6.03 |
| 2024-06-28 | -6.03 |
| 2024-06-27 | -6.08 |
| 2024-06-26 | -5.94 |
| 2024-06-25 | -5.84 |
| 2024-06-24 | -5.77 |
| 2024-06-21 | -5.80 |
| 2024-06-20 | -5.56 |
| 2024-06-18 | -5.47 |
| 2024-06-17 | -5.83 |
| 2024-06-14 | -5.72 |
| 2024-06-13 | -6.33 |
| 2024-06-12 | -6.56 |
| 2024-06-11 | -6.07 |
| 2024-06-10 | -6.16 |
| 2024-06-07 | -6.07 |
| 2024-06-06 | -6.13 |
| 2024-06-05 | -6.08 |
| 2024-06-04 | -6.00 |
| 2024-06-03 | -6.03 |
| 2024-05-31 | -5.88 |
| 2024-05-30 | -5.66 |
| 2024-05-29 | -5.58 |
| 2024-05-28 | -5.76 |
| 2024-05-24 | -5.91 |
| 2024-05-23 | -5.85 |
| 2024-05-22 | -6.02 |
| 2024-05-21 | -5.95 |
| 2024-05-20 | -6.09 |
| 2024-05-17 | -6.14 |
| 2024-05-16 | -6.26 |
| 2024-05-15 | -6.03 |